Sibrotuzumab
Based on 1 publication(s) in Google Scholar
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).
For research use only. We do not sell to patients.
- Purity: 99.05%
- CAS No.: 216669-97-5
- Molecular Weight:148.66 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sibrotuzumab
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
FAP
In Vitro
FAP is a serine protease highly expressed in cancer-associated fibroblasts (CAFs), which promote the tumor growth, invasion, and immunosuppression in a variety of solid tumors[2].
Sibrotuzumab conjugates with near-infrared photosensitizer IR700, binds specifically to FAP-positive cells FEF3 and CAF-WI38, and induces cell death under near-infrared light irradiation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CAF-FEF3 and CAF-WI38
-
Concentration:Sibrotuzumab-IR700 conjugate: 20 μg/mL
-
Incubation Time:6 h
-
Result:Inhibited cell viability.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TE8 and FEF3 xenograft mouse models[2]
-
Dosage:50 µg/mouse
-
Administration:ip, once daily for 2 days
-
Result:Inhibited tumor growth.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized FAP Protein, Human can bind Sibrotuzumab. The EC50 for this effect is 2.909 ng/mL.
Chemical Information
-
CAS No. 216669-97-5
-
Appearance Liquid
-
Molecular Weight 148.66 kDa
-
Color Colorless to light yellow
-
SMILES
[Sibrotuzumab]
-
Synonyms
BIBH 1; Anti-Human FAP Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Labelled Comp Radiopharm
Preclinical Evaluation of [225Ac]Ac-Sibrotuzumab Employing a PEG4-Macropa Site-Specific Chelation Strategy for Targeted Ablation of Cancer-Associated Fibroblasts in Desmoplastic Tumors. [Abstract]2026 Feb;69(2):e70020. PMID: 41666938
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Scott AM, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. [Content Brief]
[2]. Kobayashi T, et al., Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts Using a Humanized Anti-Fibroblast Activation Protein Antibody. Mol Cancer Ther. 2024 Jul 2;23(7):1031-1042. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sibrotuzumab Related Classifications
HY-P99269 Related Classifications
Powered by Bioz